Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | IL1B | P01584 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.41 |
| ▸ | UTS2R | Q9UKP6 | 3/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24566589 | 1.00 | BRAF (0.41) | BRAFKDRIL1BNLRP3UTS2R | |
| SCHEMBL24566899 | 1.00 | BRAF (0.41) | BRAFKDRIL1BNLRP3UTS2R | |
| SCHEMBL2203963 | 0.93 | MET (0.45) | BRAFKDRMETLIPGMEN1 | |
| SCHEMBL16904573 | 0.90 | BRAF (0.40) | BRAFKDRIL1BNLRP3MET | |
| SCHEMBL25594627 | 0.86 | BRAF (0.41) | BRAFKDRIL1BNLRP3UTS2R | |
| SCHEMBL5541792 | 0.83 | MET (0.48) | BRAFKDRMETLIPGMEN1 | |
| SCHEMBL29839849 | 0.80 | LIPG (0.43) | LIPG | |
| SCHEMBL27077125 | 0.80 | LIPG (0.43) | LIPG | |
| SCHEMBL28735359 | 0.80 | RBP4 (0.43) | KDR | |
| SCHEMBL29658331 | 0.80 | RBP4 (0.43) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2864289-B1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CB THERAPEUTICS INC (KY) | 2018-04-11 | — | — | EP | disclosed |
| EP-2864289-B1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTED AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | CB THERAPEUTICS INC (KY) | 2018-04-11 | — | — | EP | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-9840477-B2 | Cyclopropanecarboxamido-substituted aromatic compounds as anti-tumor agents | CB THERAPEUTICS INC. (KY) | 2017-12-12 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | APOLLOMICS INC. | 2016-09-29 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-9359338-B2 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents | CROWN BIOSCIENCE INC. (TAIWAN) (TW) | 2016-06-07 | — | — | US | disclosed |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | APOLLOMICS INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | APOLLOMICS INC. | 2015-07-16 | — | — | US | disclosed |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | APOLLOMICS INC. | 2015-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280664-A1 | Cyclopropanecarboxamido-Substituted Aromatic Compounds as Anti-tumor Agents | BRAF, RAF1, ARAF | BRAF 1/4885KDR 645/4885IL1B 4604/4885 |
| US-20150197511-A1 | CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS | BRAF, ARAF, RAF1 | BRAF 1/4885KDR 319/4885IL1B 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.